[Clinical evaluation of kallikrein in male infertility].
Kallikrein was orally administered to 44 patients with male infertility at a dose of 90 or 120 KU/day for three months. The sperm density, sperm motility and fertility index (F.I.) were improved in 51.1%, 37.2% and 38.9% of the treated patients, respectively. Statistical analysis showed that significant improvement was noted in sperm density and F.I. between before and after the treatment, but not in sperm motility, sperm volume nor sperm morphology. During the period of treatment, in these treated 44 patients, 4 patients (9.1%) succeeded in pregnancy.
D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D007610:Kallikreins / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D013076:Sperm Count; D013081:Sperm Motility
D007610:Kallikreins